Abstract
irAEs, along with lack of response, remain the major challenge in ICI therapy. These constraints are not unrelated, as more aggressive combinations result in higher response rates (at least in some tumors), but increase irAEs as well. Novel multidrug regimens with immune modulators may 'thread the needle' to optimize both response and toxicity concerns.
Affiliated Institutions
Related Publications
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
PURPOSE Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations tha...
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and ...
The microbiome and human cancer
BACKGROUND Historical accounts linking cancer and microbes date as early as four millennia ago. After establishment of the germ theory of infectious diseases, clinical research ...
Publication Info
- Year
- 2025
- Type
- article
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
0
OpenAlex
Cite This
Rishitha Nalabothu,
Douglas B. Johnson
(2025).
Overcoming toxicity challenges in immune checkpoint inhibitor treatment of high-risk metastatic cancers.
Expert Review of Anticancer Therapy
.
https://doi.org/10.1080/14737140.2025.2599891
Identifiers
- DOI
- 10.1080/14737140.2025.2599891